Chemotherapy (chemo) is the use of anti-cancer drugs, which are usually given into a vein. The drugs enter the bloodstream and travel throughout the body to reach and destroy cancer cells. This makes chemo useful for treating neuroblastoma, especially if it can't all be removed with surgery. The most common combination of drugs includes cisplatin (or carboplatin), cyclophosphamide, doxorubicin, vincristine, and etoposide, but others may be used.

The global Neuroblastoma Chemotherapy Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Neuroblastoma, a common malignant tumor in children, relies significantly on chemotherapy as part of its comprehensive treatment. Several chemotherapy drugs targeting neuroblastoma are already available in the market, effectively controlling disease progression by interfering with the growth and division of tumor cells. The market size has been gradually expanding due to increasing diagnosis rates and advancements in medical technology, leading to consistent growth in sales of chemotherapy drugs for pediatric neuroblastoma. Looking ahead, with the development of personalized treatments and targeted therapies, neuroblastoma chemotherapy drugs are poised to become more precise in targeting tumor cells, minimizing side effects, and enhancing therapeutic efficacy, thereby offering greater hope for affected children.

This report aims to provide a comprehensive presentation of the global market for Neuroblastoma Chemotherapy Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neuroblastoma Chemotherapy Drugs.

Report Scope

The Neuroblastoma Chemotherapy Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Neuroblastoma Chemotherapy Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Neuroblastoma Chemotherapy Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Neuroblastoma Chemotherapy Drugs Market Report

Report Metric	Details
Report Name	Neuroblastoma Chemotherapy Drugs Market
CAGR	5%
Segment by Type	Cyclophosphamide Cisplatin or Carboplatin Vincristine Doxorubicin (Adriamycin) Etoposide Other
Segment by Application	Hospital Clinic Other
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Baxter Healthcare, Ingenus Pharmaceuticals, ANI Pharmaceuticals, Teva Pharmaceuticals, Qilu Pharmaceutical, Pfizer, Hikma Pharmaceuticals, Fresenius Kabi, Accord Healthcare, Viatris
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Neuroblastoma Chemotherapy Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Neuroblastoma Chemotherapy Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Neuroblastoma Chemotherapy Drugs Market report?

Ans: The main players in the Neuroblastoma Chemotherapy Drugs Market are Baxter Healthcare, Ingenus Pharmaceuticals, ANI Pharmaceuticals, Teva Pharmaceuticals, Qilu Pharmaceutical, Pfizer, Hikma Pharmaceuticals, Fresenius Kabi, Accord Healthcare, Viatris

What are the Application segmentation covered in the Neuroblastoma Chemotherapy Drugs Market report?

Ans: The Applications covered in the Neuroblastoma Chemotherapy Drugs Market report are Hospital, Clinic, Other

What are the Type segmentation covered in the Neuroblastoma Chemotherapy Drugs Market report?

Ans: The Types covered in the Neuroblastoma Chemotherapy Drugs Market report are Cyclophosphamide, Cisplatin or Carboplatin, Vincristine, Doxorubicin (Adriamycin), Etoposide, Other

1 Neuroblastoma Chemotherapy Drugs Market Overview

1.1 Product Overview and Scope of Neuroblastoma Chemotherapy Drugs

1.2 Neuroblastoma Chemotherapy Drugs Segment by Type

1.2.1 Global Neuroblastoma Chemotherapy Drugs Market Value Comparison by Type (2024-2030)

1.2.2 Cyclophosphamide

1.2.3 Cisplatin or Carboplatin

1.2.4 Vincristine

1.2.5 Doxorubicin (Adriamycin)

1.2.6 Etoposide

1.2.7 Other

1.3 Neuroblastoma Chemotherapy Drugs Segment by Application

1.3.1 Global Neuroblastoma Chemotherapy Drugs Market Value by Application: (2024-2030)

1.3.2 Hospital

1.3.3 Clinic

1.3.4 Other

1.4 Global Neuroblastoma Chemotherapy Drugs Market Size Estimates and Forecasts

1.4.1 Global Neuroblastoma Chemotherapy Drugs Revenue 2019-2030

1.4.2 Global Neuroblastoma Chemotherapy Drugs Sales 2019-2030

1.4.3 Global Neuroblastoma Chemotherapy Drugs Market Average Price (2019-2030)

1.5 Assumptions and Limitations

2 Neuroblastoma Chemotherapy Drugs Market Competition by Manufacturers

2.1 Global Neuroblastoma Chemotherapy Drugs Sales Market Share by Manufacturers (2019-2024)

2.2 Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Manufacturers (2019-2024)

2.3 Global Neuroblastoma Chemotherapy Drugs Average Price by Manufacturers (2019-2024)

2.4 Global Neuroblastoma Chemotherapy Drugs Industry Ranking 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Neuroblastoma Chemotherapy Drugs, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Neuroblastoma Chemotherapy Drugs, Product Type & Application

2.7 Neuroblastoma Chemotherapy Drugs Market Competitive Situation and Trends

2.7.1 Neuroblastoma Chemotherapy Drugs Market Concentration Rate

2.7.2 The Global Top 5 and Top 10 Largest Neuroblastoma Chemotherapy Drugs Players Market Share by Revenue

2.7.3 Global Neuroblastoma Chemotherapy Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

2.8 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Neuroblastoma Chemotherapy Drugs Retrospective Market Scenario by Region

3.1 Global Neuroblastoma Chemotherapy Drugs Market Size by Region: 2019 Versus 2023 Versus 2030

3.2 Global Neuroblastoma Chemotherapy Drugs Global Neuroblastoma Chemotherapy Drugs Sales by Region: 2019-2030

3.2.1 Global Neuroblastoma Chemotherapy Drugs Sales by Region: 2019-2024

3.2.2 Global Neuroblastoma Chemotherapy Drugs Sales by Region: 2025-2030

3.3 Global Neuroblastoma Chemotherapy Drugs Global Neuroblastoma Chemotherapy Drugs Revenue by Region: 2019-2030

3.3.1 Global Neuroblastoma Chemotherapy Drugs Revenue by Region: 2019-2024

3.3.2 Global Neuroblastoma Chemotherapy Drugs Revenue by Region: 2025-2030

3.4 North America Neuroblastoma Chemotherapy Drugs Market Facts & Figures by Country

3.4.1 North America Neuroblastoma Chemotherapy Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.4.2 North America Neuroblastoma Chemotherapy Drugs Sales by Country (2019-2030)

3.4.3 North America Neuroblastoma Chemotherapy Drugs Revenue by Country (2019-2030)

3.4.4 U.S.

3.4.5 Canada

3.5 Europe Neuroblastoma Chemotherapy Drugs Market Facts & Figures by Country

3.5.1 Europe Neuroblastoma Chemotherapy Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.5.2 Europe Neuroblastoma Chemotherapy Drugs Sales by Country (2019-2030)

3.5.3 Europe Neuroblastoma Chemotherapy Drugs Revenue by Country (2019-2030)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Neuroblastoma Chemotherapy Drugs Market Facts & Figures by Country

3.6.1 Asia Pacific Neuroblastoma Chemotherapy Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.6.2 Asia Pacific Neuroblastoma Chemotherapy Drugs Sales by Country (2019-2030)

3.6.3 Asia Pacific Neuroblastoma Chemotherapy Drugs Revenue by Country (2019-2030)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.6.13 Philippines

3.7 Latin America Neuroblastoma Chemotherapy Drugs Market Facts & Figures by Country

3.7.1 Latin America Neuroblastoma Chemotherapy Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.7.2 Latin America Neuroblastoma Chemotherapy Drugs Sales by Country (2019-2030)

3.7.3 Latin America Neuroblastoma Chemotherapy Drugs Revenue by Country (2019-2030)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Neuroblastoma Chemotherapy Drugs Market Facts & Figures by Country

3.8.1 Middle East and Africa Neuroblastoma Chemotherapy Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.8.2 Middle East and Africa Neuroblastoma Chemotherapy Drugs Sales by Country (2019-2030)

3.8.3 Middle East and Africa Neuroblastoma Chemotherapy Drugs Revenue by Country (2019-2030)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 U.A.E

4 Segment by Type

4.1 Global Neuroblastoma Chemotherapy Drugs Sales by Type (2019-2030)

4.1.1 Global Neuroblastoma Chemotherapy Drugs Sales by Type (2019-2024)

4.1.2 Global Neuroblastoma Chemotherapy Drugs Sales by Type (2025-2030)

4.1.3 Global Neuroblastoma Chemotherapy Drugs Sales Market Share by Type (2019-2030)

4.2 Global Neuroblastoma Chemotherapy Drugs Revenue by Type (2019-2030)

4.2.1 Global Neuroblastoma Chemotherapy Drugs Revenue by Type (2019-2024)

4.2.2 Global Neuroblastoma Chemotherapy Drugs Revenue by Type (2025-2030)

4.2.3 Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Type (2019-2030)

4.3 Global Neuroblastoma Chemotherapy Drugs Price by Type (2019-2030)

5 Segment by Application

5.1 Global Neuroblastoma Chemotherapy Drugs Sales by Application (2019-2030)

5.1.1 Global Neuroblastoma Chemotherapy Drugs Sales by Application (2019-2024)

5.1.2 Global Neuroblastoma Chemotherapy Drugs Sales by Application (2025-2030)

5.1.3 Global Neuroblastoma Chemotherapy Drugs Sales Market Share by Application (2019-2030)

5.2 Global Neuroblastoma Chemotherapy Drugs Revenue by Application (2019-2030)

5.2.1 Global Neuroblastoma Chemotherapy Drugs Revenue by Application (2019-2024)

5.2.2 Global Neuroblastoma Chemotherapy Drugs Revenue by Application (2025-2030)

5.2.3 Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Application (2019-2030)

5.3 Global Neuroblastoma Chemotherapy Drugs Price by Application (2019-2030)

6 Key Companies Profiled

6.1 Baxter Healthcare

6.1.1 Baxter Healthcare Corporation Information

6.1.2 Baxter Healthcare Description and Business Overview

6.1.3 Baxter Healthcare Neuroblastoma Chemotherapy Drugs Sales, Revenue and Gross Margin (2019-2024)

6.1.4 Baxter Healthcare Neuroblastoma Chemotherapy Drugs Product Portfolio

6.1.5 Baxter Healthcare Recent Developments/Updates

6.2 Ingenus Pharmaceuticals

6.2.1 Ingenus Pharmaceuticals Corporation Information

6.2.2 Ingenus Pharmaceuticals Description and Business Overview

6.2.3 Ingenus Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales, Revenue and Gross Margin (2019-2024)

6.2.4 Ingenus Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product Portfolio

6.2.5 Ingenus Pharmaceuticals Recent Developments/Updates

6.3 ANI Pharmaceuticals

6.3.1 ANI Pharmaceuticals Corporation Information

6.3.2 ANI Pharmaceuticals Description and Business Overview

6.3.3 ANI Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales, Revenue and Gross Margin (2019-2024)

6.3.4 ANI Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product Portfolio

6.3.5 ANI Pharmaceuticals Recent Developments/Updates

6.4 Teva Pharmaceuticals

6.4.1 Teva Pharmaceuticals Corporation Information

6.4.2 Teva Pharmaceuticals Description and Business Overview

6.4.3 Teva Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Teva Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product Portfolio

6.4.5 Teva Pharmaceuticals Recent Developments/Updates

6.5 Qilu Pharmaceutical

6.5.1 Qilu Pharmaceutical Corporation Information

6.5.2 Qilu Pharmaceutical Description and Business Overview

6.5.3 Qilu Pharmaceutical Neuroblastoma Chemotherapy Drugs Sales, Revenue and Gross Margin (2019-2024)

6.5.4 Qilu Pharmaceutical Neuroblastoma Chemotherapy Drugs Product Portfolio

6.5.5 Qilu Pharmaceutical Recent Developments/Updates

6.6 Pfizer

6.6.1 Pfizer Corporation Information

6.6.2 Pfizer Description and Business Overview

6.6.3 Pfizer Neuroblastoma Chemotherapy Drugs Sales, Revenue and Gross Margin (2019-2024)

6.6.4 Pfizer Neuroblastoma Chemotherapy Drugs Product Portfolio

6.6.5 Pfizer Recent Developments/Updates

6.7 Hikma Pharmaceuticals

6.6.1 Hikma Pharmaceuticals Corporation Information

6.6.2 Hikma Pharmaceuticals Description and Business Overview

6.6.3 Hikma Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Hikma Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product Portfolio

6.7.5 Hikma Pharmaceuticals Recent Developments/Updates

6.8 Fresenius Kabi

6.8.1 Fresenius Kabi Corporation Information

6.8.2 Fresenius Kabi Description and Business Overview

6.8.3 Fresenius Kabi Neuroblastoma Chemotherapy Drugs Sales, Revenue and Gross Margin (2019-2024)

6.8.4 Fresenius Kabi Neuroblastoma Chemotherapy Drugs Product Portfolio

6.8.5 Fresenius Kabi Recent Developments/Updates

6.9 Accord Healthcare

6.9.1 Accord Healthcare Corporation Information

6.9.2 Accord Healthcare Description and Business Overview

6.9.3 Accord Healthcare Neuroblastoma Chemotherapy Drugs Sales, Revenue and Gross Margin (2019-2024)

6.9.4 Accord Healthcare Neuroblastoma Chemotherapy Drugs Product Portfolio

6.9.5 Accord Healthcare Recent Developments/Updates

6.10 Viatris

6.10.1 Viatris Corporation Information

6.10.2 Viatris Description and Business Overview

6.10.3 Viatris Neuroblastoma Chemotherapy Drugs Sales, Revenue and Gross Margin (2019-2024)

6.10.4 Viatris Neuroblastoma Chemotherapy Drugs Product Portfolio

6.10.5 Viatris Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Neuroblastoma Chemotherapy Drugs Industry Chain Analysis

7.2 Neuroblastoma Chemotherapy Drugs Key Raw Materials

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Neuroblastoma Chemotherapy Drugs Production Mode & Process

7.4 Neuroblastoma Chemotherapy Drugs Sales and Marketing

7.4.1 Neuroblastoma Chemotherapy Drugs Sales Channels

7.4.2 Neuroblastoma Chemotherapy Drugs Distributors

7.5 Neuroblastoma Chemotherapy Drugs Customers

8 Neuroblastoma Chemotherapy Drugs Market Dynamics

8.1 Neuroblastoma Chemotherapy Drugs Industry Trends

8.2 Neuroblastoma Chemotherapy Drugs Market Drivers

8.3 Neuroblastoma Chemotherapy Drugs Market Challenges

8.4 Neuroblastoma Chemotherapy Drugs Market Restraints

9 Research Finding and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Baxter Healthcare

Ingenus Pharmaceuticals

Hikma Pharmaceuticals

Fresenius Kabi

Accord Healthcare

Viatris

List of Tables

Table 1. Global Neuroblastoma Chemotherapy Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)

Table 2. Global Neuroblastoma Chemotherapy Drugs Market Value Comparison by Application (2024-2030) & (US$ Million)

Table 3. Global Neuroblastoma Chemotherapy Drugs Market Competitive Situation by Manufacturers in 2023

Table 4. Global Neuroblastoma Chemotherapy Drugs Sales (K Units) of Key Manufacturers (2019-2024)

Table 5. Global Neuroblastoma Chemotherapy Drugs Sales Market Share by Manufacturers (2019-2024)

Table 6. Global Neuroblastoma Chemotherapy Drugs Revenue (US$ Million) by Manufacturers (2019-2024)

Table 7. Global Neuroblastoma Chemotherapy Drugs Revenue Share by Manufacturers (2019-2024)

Table 8. Global Market Neuroblastoma Chemotherapy Drugs Average Price (US$/Unit) of Key Manufacturers (2019-2024)

Table 9. Global Key Players of Neuroblastoma Chemotherapy Drugs, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Neuroblastoma Chemotherapy Drugs, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Neuroblastoma Chemotherapy Drugs, Product Type & Application

Table 12. Global Key Manufacturers of Neuroblastoma Chemotherapy Drugs, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Neuroblastoma Chemotherapy Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuroblastoma Chemotherapy Drugs as of 2023)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Neuroblastoma Chemotherapy Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 17. Global Neuroblastoma Chemotherapy Drugs Sales by Region (2019-2024) & (K Units)

Table 18. Global Neuroblastoma Chemotherapy Drugs Sales Market Share by Region (2019-2024)

Table 19. Global Neuroblastoma Chemotherapy Drugs Sales by Region (2025-2030) & (K Units)

Table 20. Global Neuroblastoma Chemotherapy Drugs Sales Market Share by Region (2025-2030)

Table 21. Global Neuroblastoma Chemotherapy Drugs Revenue by Region (2019-2024) & (US$ Million)

Table 22. Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Region (2019-2024)

Table 23. Global Neuroblastoma Chemotherapy Drugs Revenue by Region (2025-2030) & (US$ Million)

Table 24. Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Region (2025-2030)

Table 25. North America Neuroblastoma Chemotherapy Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 26. North America Neuroblastoma Chemotherapy Drugs Sales by Country (2019-2024) & (K Units)

Table 27. North America Neuroblastoma Chemotherapy Drugs Sales by Country (2025-2030) & (K Units)

Table 28. North America Neuroblastoma Chemotherapy Drugs Revenue by Country (2019-2024) & (US$ Million)

Table 29. North America Neuroblastoma Chemotherapy Drugs Revenue by Country (2025-2030) & (US$ Million)

Table 30. Europe Neuroblastoma Chemotherapy Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 31. Europe Neuroblastoma Chemotherapy Drugs Sales by Country (2019-2024) & (K Units)

Table 32. Europe Neuroblastoma Chemotherapy Drugs Sales by Country (2025-2030) & (K Units)

Table 33. Europe Neuroblastoma Chemotherapy Drugs Revenue by Country (2019-2024) & (US$ Million)

Table 34. Europe Neuroblastoma Chemotherapy Drugs Revenue by Country (2025-2030) & (US$ Million)

Table 35. Asia Pacific Neuroblastoma Chemotherapy Drugs Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 36. Asia Pacific Neuroblastoma Chemotherapy Drugs Sales by Region (2019-2024) & (K Units)

Table 37. Asia Pacific Neuroblastoma Chemotherapy Drugs Sales by Region (2025-2030) & (K Units)

Table 38. Asia Pacific Neuroblastoma Chemotherapy Drugs Revenue by Region (2019-2024) & (US$ Million)

Table 39. Asia Pacific Neuroblastoma Chemotherapy Drugs Revenue by Region (2025-2030) & (US$ Million)

Table 40. Latin America Neuroblastoma Chemotherapy Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Latin America Neuroblastoma Chemotherapy Drugs Sales by Country (2019-2024) & (K Units)

Table 42. Latin America Neuroblastoma Chemotherapy Drugs Sales by Country (2025-2030) & (K Units)

Table 43. Latin America Neuroblastoma Chemotherapy Drugs Revenue by Country (2019-2024) & (US$ Million)

Table 44. Latin America Neuroblastoma Chemotherapy Drugs Revenue by Country (2025-2030) & (US$ Million)

Table 45. Middle East & Africa Neuroblastoma Chemotherapy Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 46. Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales by Country (2019-2024) & (K Units)

Table 47. Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales by Country (2025-2030) & (K Units)

Table 48. Middle East & Africa Neuroblastoma Chemotherapy Drugs Revenue by Country (2019-2024) & (US$ Million)

Table 49. Middle East & Africa Neuroblastoma Chemotherapy Drugs Revenue by Country (2025-2030) & (US$ Million)

Table 50. Global Neuroblastoma Chemotherapy Drugs Sales (K Units) by Type (2019-2024)

Table 51. Global Neuroblastoma Chemotherapy Drugs Sales (K Units) by Type (2025-2030)

Table 52. Global Neuroblastoma Chemotherapy Drugs Sales Market Share by Type (2019-2024)

Table 53. Global Neuroblastoma Chemotherapy Drugs Sales Market Share by Type (2025-2030)

Table 54. Global Neuroblastoma Chemotherapy Drugs Revenue (US$ Million) by Type (2019-2024)

Table 55. Global Neuroblastoma Chemotherapy Drugs Revenue (US$ Million) by Type (2025-2030)

Table 56. Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Type (2019-2024)

Table 57. Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Type (2025-2030)

Table 58. Global Neuroblastoma Chemotherapy Drugs Price (US$/Unit) by Type (2019-2024)

Table 59. Global Neuroblastoma Chemotherapy Drugs Price (US$/Unit) by Type (2025-2030)

Table 60. Global Neuroblastoma Chemotherapy Drugs Sales (K Units) by Application (2019-2024)

Table 61. Global Neuroblastoma Chemotherapy Drugs Sales (K Units) by Application (2025-2030)

Table 62. Global Neuroblastoma Chemotherapy Drugs Sales Market Share by Application (2019-2024)

Table 63. Global Neuroblastoma Chemotherapy Drugs Sales Market Share by Application (2025-2030)

Table 64. Global Neuroblastoma Chemotherapy Drugs Revenue (US$ Million) by Application (2019-2024)

Table 65. Global Neuroblastoma Chemotherapy Drugs Revenue (US$ Million) by Application (2025-2030)

Table 66. Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Application (2019-2024)

Table 67. Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Application (2025-2030)

Table 68. Global Neuroblastoma Chemotherapy Drugs Price (US$/Unit) by Application (2019-2024)

Table 69. Global Neuroblastoma Chemotherapy Drugs Price (US$/Unit) by Application (2025-2030)

Table 70. Baxter Healthcare Corporation Information

Table 71. Baxter Healthcare Description and Business Overview

Table 72. Baxter Healthcare Neuroblastoma Chemotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 73. Baxter Healthcare Neuroblastoma Chemotherapy Drugs Product

Table 74. Baxter Healthcare Recent Developments/Updates

Table 75. Ingenus Pharmaceuticals Corporation Information

Table 76. Ingenus Pharmaceuticals Description and Business Overview

Table 77. Ingenus Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 78. Ingenus Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product

Table 79. Ingenus Pharmaceuticals Recent Developments/Updates

Table 80. ANI Pharmaceuticals Corporation Information

Table 81. ANI Pharmaceuticals Description and Business Overview

Table 82. ANI Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 83. ANI Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product

Table 84. ANI Pharmaceuticals Recent Developments/Updates

Table 85. Teva Pharmaceuticals Corporation Information

Table 86. Teva Pharmaceuticals Description and Business Overview

Table 87. Teva Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 88. Teva Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product

Table 89. Teva Pharmaceuticals Recent Developments/Updates

Table 90. Qilu Pharmaceutical Corporation Information

Table 91. Qilu Pharmaceutical Description and Business Overview

Table 92. Qilu Pharmaceutical Neuroblastoma Chemotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 93. Qilu Pharmaceutical Neuroblastoma Chemotherapy Drugs Product

Table 94. Qilu Pharmaceutical Recent Developments/Updates

Table 95. Pfizer Corporation Information

Table 96. Pfizer Description and Business Overview

Table 97. Pfizer Neuroblastoma Chemotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 98. Pfizer Neuroblastoma Chemotherapy Drugs Product

Table 99. Pfizer Recent Developments/Updates

Table 100. Hikma Pharmaceuticals Corporation Information

Table 101. Hikma Pharmaceuticals Description and Business Overview

Table 102. Hikma Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 103. Hikma Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product

Table 104. Hikma Pharmaceuticals Recent Developments/Updates

Table 105. Fresenius Kabi Corporation Information

Table 106. Fresenius Kabi Description and Business Overview

Table 107. Fresenius Kabi Neuroblastoma Chemotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 108. Fresenius Kabi Neuroblastoma Chemotherapy Drugs Product

Table 109. Fresenius Kabi Recent Developments/Updates

Table 110. Accord Healthcare Corporation Information

Table 111. Accord Healthcare Description and Business Overview

Table 112. Accord Healthcare Neuroblastoma Chemotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 113. Accord Healthcare Neuroblastoma Chemotherapy Drugs Product

Table 114. Accord Healthcare Recent Developments/Updates

Table 115. Viatris Corporation Information

Table 116. Viatris Description and Business Overview

Table 117. Viatris Neuroblastoma Chemotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 118. Viatris Neuroblastoma Chemotherapy Drugs Product

Table 119. Viatris Recent Developments/Updates

Table 120. Key Raw Materials Lists

Table 121. Raw Materials Key Suppliers Lists

Table 122. Neuroblastoma Chemotherapy Drugs Distributors List

Table 123. Neuroblastoma Chemotherapy Drugs Customers List

Table 124. Neuroblastoma Chemotherapy Drugs Market Trends

Table 125. Neuroblastoma Chemotherapy Drugs Market Drivers

Table 126. Neuroblastoma Chemotherapy Drugs Market Challenges

Table 127. Neuroblastoma Chemotherapy Drugs Market Restraints

Table 128. Research Programs/Design for This Report

Table 129. Key Data Information from Secondary Sources

Table 130. Key Data Information from Primary Sources

List of Figures

Figure 1. Product Picture of Neuroblastoma Chemotherapy Drugs

Figure 2. Global Neuroblastoma Chemotherapy Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)

Figure 3. Global Neuroblastoma Chemotherapy Drugs Market Share by Type in 2023 & 2030

Figure 4. Cyclophosphamide Product Picture

Figure 5. Cisplatin or Carboplatin Product Picture

Figure 6. Vincristine Product Picture

Figure 7. Doxorubicin (Adriamycin) Product Picture

Figure 8. Etoposide Product Picture

Figure 9. Other Product Picture

Figure 10. Global Neuroblastoma Chemotherapy Drugs Market Value Comparison by Application (2024-2030) & (US$ Million)

Figure 11. Global Neuroblastoma Chemotherapy Drugs Market Share by Application in 2023 & 2030

Figure 12. Hospital

Figure 13. Clinic

Figure 14. Other

Figure 15. Global Neuroblastoma Chemotherapy Drugs Revenue, (US$ Million), 2019 VS 2023 VS 2030

Figure 16. Global Neuroblastoma Chemotherapy Drugs Market Size (2019-2030) & (US$ Million)

Figure 17. Global Neuroblastoma Chemotherapy Drugs Sales (2019-2030) & (K Units)

Figure 18. Global Neuroblastoma Chemotherapy Drugs Average Price (US$/Unit) & (2019-2030)

Figure 19. Neuroblastoma Chemotherapy Drugs Report Years Considered

Figure 20. Neuroblastoma Chemotherapy Drugs Sales Share by Manufacturers in 2023

Figure 21. Global Neuroblastoma Chemotherapy Drugs Revenue Share by Manufacturers in 2023

Figure 22. The Global 5 and 10 Largest Neuroblastoma Chemotherapy Drugs Players: Market Share by Revenue in 2023

Figure 23. Neuroblastoma Chemotherapy Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023

Figure 24. Global Neuroblastoma Chemotherapy Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Figure 25. North America Neuroblastoma Chemotherapy Drugs Sales Market Share by Country (2019-2030)

Figure 26. North America Neuroblastoma Chemotherapy Drugs Revenue Market Share by Country (2019-2030)

Figure 27. U.S. Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 28. Canada Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 29. Europe Neuroblastoma Chemotherapy Drugs Sales Market Share by Country (2019-2030)

Figure 30. Europe Neuroblastoma Chemotherapy Drugs Revenue Market Share by Country (2019-2030)

Figure 31. Germany Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 32. France Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 33. U.K. Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 34. Italy Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 35. Russia Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 36. Asia Pacific Neuroblastoma Chemotherapy Drugs Sales Market Share by Region (2019-2030)

Figure 37. Asia Pacific Neuroblastoma Chemotherapy Drugs Revenue Market Share by Region (2019-2030)

Figure 38. China Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 39. Japan Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 40. South Korea Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 41. India Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 42. Australia Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 43. Taiwan Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 44. Indonesia Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 45. Thailand Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 46. Malaysia Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 47. Philippines Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 48. Latin America Neuroblastoma Chemotherapy Drugs Sales Market Share by Country (2019-2030)

Figure 49. Latin America Neuroblastoma Chemotherapy Drugs Revenue Market Share by Country (2019-2030)

Figure 50. Mexico Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 51. Brazil Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 52. Argentina Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 53. Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales Market Share by Country (2019-2030)

Figure 54. Middle East & Africa Neuroblastoma Chemotherapy Drugs Revenue Market Share by Country (2019-2030)

Figure 55. Turkey Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 56. Saudi Arabia Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 57. U.A.E Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 58. Global Sales Market Share of Neuroblastoma Chemotherapy Drugs by Type (2019-2030)

Figure 59. Global Revenue Market Share of Neuroblastoma Chemotherapy Drugs by Type (2019-2030)

Figure 60. Global Neuroblastoma Chemotherapy Drugs Price (US$/Unit) by Type (2019-2030)

Figure 61. Global Sales Market Share of Neuroblastoma Chemotherapy Drugs by Application (2019-2030)

Figure 62. Global Revenue Market Share of Neuroblastoma Chemotherapy Drugs by Application (2019-2030)

Figure 63. Global Neuroblastoma Chemotherapy Drugs Price (US$/Unit) by Application (2019-2030)

Figure 64. Neuroblastoma Chemotherapy Drugs Value Chain

Figure 65. Neuroblastoma Chemotherapy Drugs Production Process

Figure 66. Channels of Distribution (Direct Vs Distribution)

Figure 67. Distributors Profiles

Figure 68. Bottom-up and Top-down Approaches for This Report

Figure 69. Data Triangulation

Figure 70. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

RELATED REPORTS

Global Oncology Imaging Equipment Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-1U15802

Wed Aug 28 00:00:00 UTC 2024

Add to Cart

Global HER2 Tumor Marker Testing Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-27D15553

Wed Aug 28 00:00:00 UTC 2024

Add to Cart

Global Targeted Radiotherapy Drug Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-2U15903

Wed Aug 28 00:00:00 UTC 2024

Add to Cart

Global Cell-Free Circulating Tumor DNA (ctDNA) Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-2W15676

Tue Aug 27 00:00:00 UTC 2024

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions